LLY is beginning to attract renewed buying interest following its recent retracement. The stock remains in a strong uptrend, continuing to make higher highs and higher lows while trading above well-aligned 20 and 50-day moving averages, signaling that bullish momentum remains intact.
Eli Lilly & Co. is a $1.11 trillion market capitalization company that engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. Its portfolio spans several therapeutic areas, including diabetes, oncology, immunology, neuroscience, and other innovative medicines and treatments. The company’s leadership in the rapidly growing obesity and diabetes markets, coupled with its robust drug development pipeline, positions it favorably for long-term growth.
LLY is a wide economic moat company that has delivered significant and consistent revenue and earnings-per-share growth over the past three quarters. The company continues to generate exceptional profitability, with operating and net margins of 49% and 37%, respectively. Return on equity (ROE) and return on invested capital (ROIC) stand at an impressive 108% and 42%, underscoring management’s ability to efficiently deploy capital and create shareholder value. Eli Lilly also maintains a healthy liquidity position, with a current ratio of 1.5x and a debt-to-equity ratio of 1.4x, providing financial flexibility to support continued investment in research, development, and strategic growth initiatives.